Skip to main content

Samsara BioCapital — Portfolio, Page 6

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

132
Companies
$12.1B
Total invested
$113.4M
Avg. check
11
Industries
Biotechnology 12Health Care 10Pharmaceutical 6Therapeutics 5Medical 4Clinical Trials 2+5 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 121132 of 132
SanReno Therapeutics
November 2021

SanReno Therapeutics develop, manufacture and commercialize kidney disease therapies.

Biotechnology · Beijing$40.0M Undisclosed
Ablaze Pharmaceuticals
November 2021

Ablaze Pharmaceuticals is a clinical-stage pharmaceutical company.

Biotechnology · Jingan$75.0M Series A
Science 37
October 2021

Science 37 is a clinical research company that facilitates universal participation in clinical trials for patients and providers.

Biotechnology · Culver City$200.0M Post Ipo Equity
Exo Therapeutics
October 2021

Exo Therapeutics is a small molecule drug discovery and development company.

Biotechnology · Cambridge$78.0M Series B
Neurogastrx
August 2021

A private biopharmaceutical company .

Biotechnology · Woburn$60.0M Series B
Bolt Biotherapeutics
June 2021

Bolt Biotherapeutics is a biotechnology company that develops a platform for cancer immunotherapy.

Biotechnology · Redwood City$15.0M Post Ipo Equity
Vedere Bio ll
May 2021

Vedere Bio is developing gene therapy products to restore functional vision to patients who have suffered vision loss.

Biotechnology · Cambridge$77.0M Series A
Flame Biosciences
September 2020

Flame Biosciences is a clinical-stage company focused on therapies for cancer and other inflammatory diseases.

Biotechnology · New York$100.0M Series Unknown
Rain Oncology
September 2020

Rain Oncology is a operator of a clinical stage biotechnology company.

Biopharma · Newark$63.0M Series B
Atreca
July 2020

Atreca develops a technology to identify the set of antibodies produced during an immune response, without prior knowledge of an antigen.

Biotechnology · South San Francisco$125.0M Post Ipo Equity
Velicept Therapeutics
November 2019

Velicept Therapeutics is a privately held clinical development

Biotechnology · Malvern$6.0M Debt Financing
Levo Therapeutics
November 2019

Levo Therapeutics is a biomedical research and development services intended to treat the multisystem neurodevelopmental disorder.

Biotechnology · Skokie$40.0M Series Unknown

Where Samsara BioCapital invests

Biotechnology12
Health Care10
Pharmaceutical6
Therapeutics5
Medical4
Clinical Trials2

About Samsara BioCapital's portfolio

How many companies has Samsara BioCapital invested in?

Samsara BioCapital has invested in 132 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Samsara BioCapital invest in?

Samsara BioCapital's top investment sectors include Biotechnology, Health Care, Pharmaceutical, Therapeutics, Medical. The firm invests across 11 different industry categories.

What is Samsara BioCapital's largest investment?

Among tracked funding rounds, Science 37 received $200.0M in a Post Ipo Equity round. Samsara BioCapital's total known invested capital is $12.1B.

What is the average investment size for Samsara BioCapital?

Samsara BioCapital's average investment size is $113.4M across its portfolio of 132 companies.

What are Samsara BioCapital's most recent investments?

Recent Samsara BioCapital portfolio additions include SanReno Therapeutics, Ablaze Pharmaceuticals, Science 37, Exo Therapeutics, Neurogastrx. These companies were founded in 2020 or later.

Reach the founders behind these 132 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →